On the spotlight

Project Objectives Recently, the therapeutic scenario of advanced non-small cell lung cancer (NSCLC) is changed with the introduction into clinical practice of "immune check-points" (PD-1 / PDL-1) inhibitors, able to reactivate the immune response against the tumor. These immunotherapeutic agents have greatly improved patients outcome in terms of overall survival. However, a lar...

Focus on

Project Objectives   Recently, the encouraging results of phase III trials led to the approval of immunotherapy as a second-line treatment in patients with clear cell renal cell carcinoma (ccRCC). However, currently, no predictive biomarkers of efficacy are available since PD-L1 expression, validated biomarker in lung cancer, does not predict the response to immunotherapy in cc...
Project Objectives Several target therapies have recently been approved for the treatment of metastatic clear cell renal cell carcinoma. These drugs have a strong inhibitory activity for several tyrosine kinase receptors, including MET and vascular endothelial growth factor receptors (VEGFR), molecular pathways involved in tumor progression, metastasis development and angiogenesis. It is ...
Project Objectives Third generation cyclin-dependent kinase inhibitors (CDK4/6), such as ribociclib, palbociclib and abemaciclib, have shown remarkable clinical efficacy and low toxicity profiles in the treatment of metastatic breast cancer ER+/HER-. Activated CDK4/6 kinases, following their binding to cyclin D, regulate phases G1 to S of the cell cycle by phosphorylation of the Rb protei...